Evolent Health (EVH) to Post Earnings on Thursday

Evolent Health (NYSE:EVH) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.01) per share and revenue of $597.6970 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. The business had revenue of $496.25 million during the quarter, compared to analysts’ expectations of $534.00 million. Evolent Health had a positive return on equity of 0.36% and a negative net margin of 26.29%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $0.06 EPS. On average, analysts expect Evolent Health to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Stock Performance

EVH opened at $3.29 on Thursday. The company has a debt-to-equity ratio of 2.46, a current ratio of 1.32 and a quick ratio of 1.32. The business has a fifty day simple moving average of $4.83 and a 200 day simple moving average of $3.75. Evolent Health has a 1 year low of $2.10 and a 1 year high of $10.30. The company has a market capitalization of $370.62 million, a PE ratio of -0.69 and a beta of 0.76.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in Evolent Health during the fourth quarter worth about $106,000. Invesco Ltd. grew its stake in Evolent Health by 30.4% during the fourth quarter. Invesco Ltd. now owns 392,282 shares of the technology company’s stock worth $1,569,000 after buying an additional 91,370 shares in the last quarter. nVerses Capital LLC bought a new position in Evolent Health in the 4th quarter valued at about $109,000. Tudor Investment Corp ET AL increased its holdings in Evolent Health by 1.9% in the 4th quarter. Tudor Investment Corp ET AL now owns 702,121 shares of the technology company’s stock valued at $2,808,000 after buying an additional 12,859 shares during the period. Finally, Quadrature Capital Ltd increased its holdings in Evolent Health by 128.1% in the 4th quarter. Quadrature Capital Ltd now owns 159,815 shares of the technology company’s stock valued at $639,000 after buying an additional 89,742 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on EVH shares. Weiss Ratings cut shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 21st. TD Cowen cut their price objective on shares of Evolent Health from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday. Canaccord Genuity Group increased their target price on shares of Evolent Health from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Citigroup reaffirmed a “sell” rating and set a $6.75 target price (up from $5.50) on shares of Evolent Health in a report on Thursday, July 23rd. Finally, Truist Financial downgraded shares of Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 price target for the company. in a research report on Tuesday, June 30th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.16.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.